EHA2024| 和黄HMPL-306治疗IDH1/2突变r/rAML患者临床I期数数据
华创新药 2024-05-15 23:31 广东
For efficacy, except for one patient with non-hotspot mutations, CR+CRh rates of 150mg+250mg level (N=35) was 26.7% (4/15) and 30% (6/20) in mIDH1 and mIDH2 pts, and the median OS was 13.4 months and 13.1 months in mIDH1 and mIDH2 pts, respectively. Sensitivity analysis (excludingFLT3 and RAS hotspot mutations) at 150mg and 250mg levels showed that the CR+CRh rates could reach 33.3% (4/12) and 35.7% (5/14). The median OS was not reached in mIDH1 pts and 14.2 months in mIDH2 pts, respectively. At RP2D level, CR+CRh rates were 45.5% (5/11) and 50% (6/12) in pts with mIDH1 and mIDH2, respectively. When pts withFLT3 and RAS mutat ions were excluded, CR+CRh rates increased to 50% (4/8) and 62% (5/8). The median OS was not reached in pts with either mIDH1 or mIDH2 (Table 1).
